Skip to main content
Top
Published in: International Urology and Nephrology 2/2018

01-02-2018 | Nephrology - Original Paper

Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2

Authors: Libin Ma, Hua Li, Shuchao Zhang, Xiaoling Xiong, Kean Chen, Peiwu Jiang, Kang Jiang, Gang Deng

Published in: International Urology and Nephrology | Issue 2/2018

Login to get access

Abstract

Background

Emodin is a natural active component extracted from Chinese herbs. In this study, we investigated the therapeutic effect of emodin on surgery-induced renal fibrosis in rat. Moreover, the function of Smad ubiquitination regulatory factor 2 (Smurf 2) was further studied in vitro.

Methods

The renal fibrosis rat model was established via 5/6 renal mass reduction. The histopathological abnormalities of renal tissues in rats were tested via staining method and microscopic examination. Renal function indicators, the serum creatinine, blood urea nitrogen and total urinary protein were measured via spectrophotometric method. The renal tissues were tested via Western blotting and real-time quantitative PCR. Moreover, Smurf 2 protein expression under different conditions and its regulatory function in vitro was measured via Western blotting.

Results

Our results showed that the histopathological abnormalities, the decrease in rat body weight and the abnormal renal function caused by renal fibrosis were improved by emodin. Further, mRNA expression of TGF-β1 was decreased by emodin. Furthermore, extracellular matrix (ECM) components as well as TGF-β1/Smad signaling-related Smurf 2 were decreased by emodin both in vivo and in vitro. The protein level of mothers against decapentaplegic homolog 7 (Smad7) was up-regulated. In addition, ECM components were increased by Smurf 2 over-expression and these effects were weakened by emodin co-treatment in vitro.

Conclusion

Emodin showed an anti-fibrosis effect in surgery-induced renal fibrotic rats. And this effect was potentially achieved via down-regulating expressions of TGF-β1 and Smurf 2 and up-regulating Smad7 expression.
Literature
3.
go back to reference Rodriguez-Pena A, Prieto M, Duwel A, Rivas JV, Eleno N, Perez-Barriocanal F, Arevalo M, Smith JD, Vary CP, Bernabeu C, Lopez-Novoa JM (2001) Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant 16(Suppl 1):34–39CrossRefPubMed Rodriguez-Pena A, Prieto M, Duwel A, Rivas JV, Eleno N, Perez-Barriocanal F, Arevalo M, Smith JD, Vary CP, Bernabeu C, Lopez-Novoa JM (2001) Up-regulation of endoglin, a TGF-beta-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction. Nephrol Dial Transplant 16(Suppl 1):34–39CrossRefPubMed
6.
go back to reference Wolf G (1998) Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 13(5):1131–1142CrossRefPubMed Wolf G (1998) Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 13(5):1131–1142CrossRefPubMed
13.
go back to reference Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6(6):1365–1375CrossRefPubMed Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL (2000) Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6(6):1365–1375CrossRefPubMed
16.
go back to reference Yang T, Kong B, Kuang Y, Cheng L, Gu J, Zhang J, Shu H, Yu S, Yang X, Cheng J, Huang H (2015) Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1). Int J Clin Exp Pathol 8(3):3418–3425PubMedPubMedCentral Yang T, Kong B, Kuang Y, Cheng L, Gu J, Zhang J, Shu H, Yu S, Yang X, Cheng J, Huang H (2015) Emodin plays an interventional role in epileptic rats via multidrug resistance gene 1 (MDR1). Int J Clin Exp Pathol 8(3):3418–3425PubMedPubMedCentral
21.
go back to reference Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenfuhrer J, Hasan AA, Tammen H, Alter M, Klein T, Ueda S, Yamagishi S, Okuda S, Hocher B (2016) The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int 89(5):1049–1061. https://doi.org/10.1016/j.kint.2016.01.016 CrossRefPubMed Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenfuhrer J, Hasan AA, Tammen H, Alter M, Klein T, Ueda S, Yamagishi S, Okuda S, Hocher B (2016) The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int 89(5):1049–1061. https://​doi.​org/​10.​1016/​j.​kint.​2016.​01.​016 CrossRefPubMed
23.
go back to reference Raij L, Azar S, Keane W (1984) Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26(2):137–143CrossRefPubMed Raij L, Azar S, Keane W (1984) Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26(2):137–143CrossRefPubMed
24.
go back to reference Abe S, Amagasaki Y, Iyori S, Konishi K, Kato E, Sakaguchi H (1989) Significance of tubulointerstitial lesions in biopsy specimens of glomerulonephritic patients. Am J Nephrol 9(1):30–37CrossRefPubMed Abe S, Amagasaki Y, Iyori S, Konishi K, Kato E, Sakaguchi H (1989) Significance of tubulointerstitial lesions in biopsy specimens of glomerulonephritic patients. Am J Nephrol 9(1):30–37CrossRefPubMed
32.
Metadata
Title
Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2
Authors
Libin Ma
Hua Li
Shuchao Zhang
Xiaoling Xiong
Kean Chen
Peiwu Jiang
Kang Jiang
Gang Deng
Publication date
01-02-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1757-x

Other articles of this Issue 2/2018

International Urology and Nephrology 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.